Navigation path

Horizon prize

News Alert

The EU boosts vaccine research with €30 Million

Brussels, 29 September 2011

A new EU funded collaborative research programme - Advanced Immunization Technologies (ADITEC)- will accelerate the development of novel and powerful immunization technologies for the next generation of human vaccines. €30 Million of European Commission co-funding will enable ADITEC to establish a strong platform for innovation in a key area for human health. A consortium of scientists from 42 research and industry bodies in 13 countries will work together on the project, which will work on a wide range of crucial aspects of vaccination; from basic research and new technologies to clinical trials and public health. The support for this project underlines the importance of the vaccine sector in effective healthcare, and gives a boost in a key innovation area for the European health industry.

Máire Geoghegan-Quinn, European Commissioner for Research, Innovation and Science, said: “New technologies are opening the door to fight those diseases for which vaccines could not be developed so far.  However, researchers in a single laboratory cannot tackle modern vaccine science in isolation, which is why we are bringing together some of Europe's top researchers in this area. By joining forces and pooling knowledge and expertise, we can take a big step towards transforming the medicine of the future."

ADITEC comprises a team of top European universities and research institutions complemented by US groups working on systems biology and adjuvants -components of vaccine formulations that enhance the efficacy of vaccines-. The project is driven by a number of key European industries, both big pharmaceutical and smaller biotechnology companies. These corporations are focusing on specific innovative technologies that allow for better and safer vaccines. The World Health Organization is supporting the project as a senior partner, ensuring that cross-cutting global health aspects are taken into consideration.

This high-impact project will seek to achieve a number of clear goals.  It will focus on improved potency and safety of vaccines and their components, novel routes and devices for administration of vaccines optimized vaccination strategies and optimized formulations and vaccination methods for different age groups.  It will also look at giving better insight into the effects of gender, chronic diseases and genetic variation on vaccination. Finally, ADITEC will apply new technologies and it will help to establish them widely throughout Europe.

Links
EU Research on Immunisation
Brochure on EU-funded Human Vaccines
Explanatory memorandum for High Impact research initiative Projects

Details of ADITEC project
Start date: 01/10/2011
End date: 30/09/2016
Project cost: €41.00 million
EU contribution: €29.98 million
Coordinator: Rino Rappuoli & Donata Medaglini, Sclavo Vaccines Association (SVA), Siena (Italy), email: info@associazionesclavo.org, Tel: + 39-0577-233307

Participants
Sclavo Vaccines Association, Italy
Statens Serum Institut, Denmark
St George University of London, United Kingdom
Max Planck Institute for Infection Biology, Germany
University of Siena, Italy
Institute Pasteur, France
University of Oxford, United Kingdom
University of Geneva, Switzerland
Novartis Vaccines and Diagnostics s.r.l., Italy
Intercell, Austria
University of Goteborg, Sweden
Leiden University and Medical Centre, The Netherlands
Emory University Atlanta, USA
Tuberculosis Vaccine Initiative, The Netherlands
Institute for Biomedical Aging Research, Austria
Infectious Disease Research Institute Seattle, USA
Utrecht University, The Netherlands
Fondazione Humanitas per la Ricerca, Italy
Fondazione per l’Istituto di Ricerca in Biomedicina, Switzerland
Istituto Superiore di Sanità, Italy
Kings College London, United Kingdom
World Health Organization, Switzerland
French Atomic Energy, France
Institut de Biologie et Chimie des Protéines, France
Erasmus Medical Center, The Netherlands
ALTA s.r.l.u, Italy
Medicine in need, France
deCODE Genetics, Iceland
Okairos, Italy
Sigmoid Pharma, Ireland
Vaccibody, Norway
Pevion Biotech, Switzerland
Duotol AB, Sweden
Crossbeta Biosciences, The Netherlands
Microbiotec srl, Italy
ArenaVax, Switzerland
Xbrane Bioscience AB, Sweden
Bioneedle Group, The Netherlands
Novartis Vaccines Institute for Global Health s.r.l, Italy
National Institute for Biological Standards and Control, United Kingdom
Seattle Biomedical Research Institute, USA
Imperial College London, UK

Contacts:
Michael Jennings (+32 2 296 33 88)
Monika Wcislo (+32 2 298 65 95)